Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Depressant+1 more
Opioid systemmorphine, fentanyl, DADLE +1 moremorphine, fentanyl, DADLE, other mu-opioid receptor agonists show less
Sufentanil
Sufentanil is a synthetic opioid of the anilidopiperidine class. It is the most potent opioid in routine clinical use — several times stronger than fentanyl. It activates opioid receptors in the brain and spinal cord, suppressing pain and depressing the drive to breathe.
Sufentanil is a synthetic opioid of the anilidopiperidine class. It is the most potent opioid in widespread clinical use, 500–1,000× stronger than morphine and 5–10× more potent than fentanyl.[1] Sufentanil is a full µ-opioid receptor agonist, producing its effects by suppressing pain signaling and depressing respiratory drive.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Depressant+1 more
Opioid systemmorphine, fentanyl, DADLE +1 moremorphine, fentanyl, DADLE, other mu-opioid receptor agonists show less
Synthesized in 1974 at Janssen Pharmaceutica by Paul Janssen's team, it emerged from the same structural research program that produced fentanyl.[1] The FDA approved it for injection in 1984, and it became the opioid of choice in cardiac surgery;[2] a sublingual tablet (Dsuvia) gained controversial approval in 2018.[3] It remains primarily a hospital drug with minimal documented presence in illicit markets.
Subjective effects include complete pain suppression, heavy sedation, dissolution of anxiety, and a warm euphoria that compresses awareness into quiet stillness. The experience is defined by what it removes — pain and distress disappear, and consciousness narrows toward silence. At high doses, breathing slows visibly; nausea and chest wall stiffness are characteristic unwanted effects.
Physical dependence develops rapidly, and respiratory depression — breathing slowing to a stop — is the primary cause of death in overdose.[4] The margin between an analgesic dose and a fatal one is narrow in humans, even though preclinical studies give sufentanil the widest safety margin of any tested opioid.[4] Five decades of clinical anesthesia use underpin the risk profile, but no controlled human studies on subjective effects or chronic toxicity have been published.
History[edit]
Discovery
Sufentanil (laboratory designation R 30 730) was synthesized in 1974 at Janssen Pharmaceutica by Paul Janssen's team, emerging from fifteen years of systematic modification of fentanyl.[1] The key changes — a sulfur-containing thiophene ring and a methoxymethyl group — dramatically increased receptor affinity and brain penetration. Foundational preclinical work published in 1976 established its potency at over 2,000× morphine and the highest preclinical therapeutic index of any tested opioid.[4]
Clinical adoption
The FDA approved sufentanil injection in 1984 for use in cardiac and balanced anesthesia.[2] Its hemodynamic stability and high potency made it the preferred opioid for cardiac surgery. Two alternative delivery systems — an implantable pump and a transdermal patch — were developed for chronic pain but neither reached FDA approval.[5]
Sublingual formulation and controversy
On November 2, 2018, the FDA approved Dsuvia — a 30 µg sublingual tablet for acute pain in medically supervised settings.[3] The approval drew public opposition from the FDA's own advisory committee chair over diversion risk during the opioid crisis. Unlike fentanyl, sufentanil has not appeared prominently in street drug markets; documented diversion overwhelmingly involves healthcare professionals with anesthesia access.[6]
The name sufentanil follows Janssen's naming convention — the -fentanil suffix links it to its parent compound, while su- derives from its thiophene (sulfur-containing) substitution. The compound carries no street names; documented use outside hospitals overwhelmingly involves healthcare professionals rather than recreational users.[6]
Chemistry[edit]
Structural class
Sufentanil belongs to the anilidopiperidine chemical class — the same family as fentanyl, alfentanil, and carfentanil.[7] This class was built through systematic modification of meperidine, with fentanyl as its first major compound.[1] Its molecular formula is C₂₂H₃₀N₂O₂S, molecular weight 386.6 g/mol.[8] It is administered clinically as a citrate salt to improve water solubility for injection.[2]
Structure–activity relationships
Two structural changes distinguish sufentanil from fentanyl: a sulfur-containing thiophene ring replaces fentanyl's phenyl group, and a methoxymethyl group is added at the piperidine ring.citation needed Together these modifications produce a compound 5–10× more potent than fentanyl.[2] The primary metabolite, norsufentanil, has substantially lower opioid activity.[9]
Pharmacology[edit]
Mechanism of action
Sufentanil is a full agonist at the µ-opioid receptor — binding with the highest measured affinity of any approved opioid drug,[10] substantially exceeding fentanyl.[10] This opioid receptor activation suppresses neuronal excitability: pain signals are dampened, breathing slows, and sedation follows.[11]
Pharmacokinetics
After intravenous administration, sufentanil rapidly redistributes from blood into body tissues — roughly 98% within 30 minutes.[12] This redistribution, not metabolic breakdown, explains the short clinical duration of standard doses.[12] Protein binding is approximately 93% in healthy adults and lower in neonates.[2]
Age-dependent variation
The half-life is approximately 2.7 hours in adults, 1.6 hours in children, and 7.2 hours in newborns — a nearly threefold difference reflecting immature liver metabolism that requires careful dose adjustment.[13] Sufentanil is broken down by the CYP3A4 liver enzyme into norsufentanil,[14] with approximately 80% of a dose eliminated within 24 hours.[2]
Neuroscience[edit]
Where it acts
Sufentanil activates opioid receptors in the brainstem and spinal cord to relieve pain — triggering descending pathways that suppress pain signals before they reach conscious awareness.[11] At the spinal level, direct suppression of the pain relay is the mechanism behind epidural and spinal anesthesia.
Euphoria and the reinforcing pull of the drug come from opioid receptor activation in the brain's reward circuit, flooding reward regions with dopamine.[11] The most dangerous effect — slowed breathing — results from receptor activation in the brainstem's breathing centers, suppressing both the rhythm and drive to breathe.[2]
Tolerance and neuroadaptation
Chronic exposure changes how opioid receptors signal. In the spinal cord, receptors uncouple from their inhibitory pathways;[15] in higher brain regions, signaling switches from inhibitory to excitatory — a molecular marker of physical dependence.[16] Sufentanil can also paradoxically increase pain sensitivity through a pathway distinct from morphine, which may explain clinical reports of relief when switching to sufentanil from morphine.[17][18]
Whether sufentanil's efficient receptor recycling translates to slower tolerance development in humans — compared to morphine at equivalent doses — has never been tested in a controlled study. No data exist on its functional selectivity, the signaling balance that shapes the ratio of analgesia to respiratory depression. The pain-sensitizing pathway identified in mouse models[17] has not been confirmed in humans.
Subjective Effects[edit]
Sufentanil produces the experience of a pure, high-potency opioid. Pain dissolves almost instantly. What follows is deep weighted stillness — anxiety fades, consciousness narrows, and mental activity quiets to near-silence. At analgesic doses the experience is dominated by relief and calm; at higher doses awareness compresses toward loss of consciousness.
Compared to fentanyl, the qualitative experience is similar but compressed into a fraction of the dose, with clinical reports of greater hemodynamic stability. Compared to morphine, the effect arrives within minutes rather than hours and produces less nausea and histamine-related itching. The opioid character is pure — without the added dimensions that drugs like tramadol introduce through serotonin activity.
Synthesized in 1974 at Janssen Pharmaceutica as part of the structure–activity program that produced fentanyl,[3] sufentanil was approved for injection in 1984 and became a cornerstone of cardiac anesthesia.[1] A sublingual formulation (Dsuvia, 30 µg) received controversial FDA approval in 2018 for acute pain in medically supervised settings.[4] The compound remains primarily a hospital-use drug with minimal documented presence in illicit markets.
Subjective effects include profound analgesia, sedation, anxiolysis, and euphoria. The experience is that of a pure, high-potency opioid — pain and distress dissolve rapidly into deep, weighted stillness in which consciousness narrows and mental activity quiets to near-silence. Respiratory slowing, chest wall rigidity at high doses, and nausea are characteristic unsought effects.
Sufentanil produces rapid physical dependence, and respiratory depression is the primary cause of death in overdose.[5] Despite the highest preclinical therapeutic index of any major opioid, the margin between analgesia and respiratory depression in humans remains narrow enough to mandate continuous monitoring.[5] Five decades of clinical anesthesia data underpin the safety profile, though no controlled subjective-effects studies or sufentanil-specific chronic toxicity research have been published.
History[edit]
Discovery
Sufentanil (laboratory designation R 30 730) was synthesized in 1974 at Janssen Pharmaceutica in Beerse, Belgium, by the team led by Paul Janssen.[3] Janssen had synthesized fentanyl in 1959 through systematic modification of meperidine, then spent fifteen years developing increasingly potent anilidopiperidine analogs. Sufentanil emerged as a thiophene-substituted variant incorporating a methoxymethyl group at the piperidine ring — modifications that dramatically increased receptor affinity and lipophilicity. The foundational preclinical study, published in 1976 by Niemegeers and colleagues, established its potency at over 2,000× morphine and the highest preclinical therapeutic index of any tested opioid.[5]
Clinical adoption
In 1984, the FDA approved sufentanil citrate injection (brand name Sufenta) for use as an analgesic adjunct in balanced anesthesia and as a primary agent in cardiac surgery.[1] It rapidly became the opioid of choice in cardiac anesthesia owing to its hemodynamic stability, high potency, and wide therapeutic margin. Two alternative delivery systems — an implantable osmotic pump (Chronogesic) and a transdermal patch (TRANSDUR-Sufentanil) — were developed for chronic pain but neither received FDA approval.[6]
Sublingual formulation and controversy
On November 2, 2018, the FDA approved Dsuvia (sufentanil sublingual tablet, 30 µg) for acute pain severe enough to require an opioid in medically supervised settings.[4] The approval drew public opposition from Public Citizen and the chair of the FDA's own advisory committee, who cited diversion risk during the ongoing opioid crisis. Unlike fentanyl, sufentanil has not been prominently featured in illicit drug market surveillance — its primary diversion risk is occupational, documented in forensic case series involving healthcare professionals with access to anesthesia supplies.[7]
The name sufentanil follows Janssen Pharmaceutica's naming convention for the anilidopiperidine series — the -fentanil suffix links it to its parent compound fentanyl, while the su- prefix derives from its thiophene (sulfur-containing) substitution. The compound carries no widespread street names; its use outside hospital settings is rare, and documented diversion cases overwhelmingly involve healthcare professionals rather than street-level distribution.[7]
Chemistry[edit]
Structural class
Sufentanil belongs to the anilidopiperidine chemical class — the same family as fentanyl, alfentanil, remifentanil, and carfentanil.[8] The anilidopiperidine scaffold was first explored by Paul Janssen through systematic modification of meperidine, yielding fentanyl as the prototypical member.[3]
Sufentanil retains the core 4-anilidopiperidine structure but introduces two key modifications: a 2-thienylethyl group replacing fentanyl's phenethyl substituent at the piperidine nitrogen, and a methoxymethyl group at the 4-position of the piperidine ring. The thiophene (sulfur-containing) heterocycle distinguishes sufentanil from fentanyl's phenyl group and contributes to its greater receptor affinity and lipophilicity.
Molecular properties
The molecule contains a piperidine ring bearing a propionamide group linked to a phenyl ring (the anilide moiety), a methoxymethyl ether at C-4, and a thiophene ring connected through an ethylene bridge to the piperidine nitrogen. Sufentanil is administered clinically as the citrate salt, which improves aqueous solubility for injection formulations at concentrations of 50 µg/mL.[1]
Stereochemistry
Sufentanil has a chirality center at C-4 of the piperidine ring due to the methoxymethyl substituent. The clinically used compound is the racemate.[9] No published studies on differences in potency between the individual enantiomers were identified — a gap relative to several other chiral opioids where enantioselective pharmacology has been characterized.
Structure–activity relationships
Two structural modifications distinguish sufentanil from fentanyl and account for its increased potency. The replacement of fentanyl's phenethyl group with a 2-thienylethyl group introduces a sulfur-containing aromatic ring that enhances binding interactions at the µ-opioid receptor. The addition of a methoxymethyl group at the piperidine 4-position increases lipophilicity, accelerating CNS penetration and contributing to the compound's rapid onset.citation needed
Together, these changes produce a compound approximately 5–10× more potent than fentanyl and 500–1,000× more potent than morphine.[1] The primary metabolite, norsufentanil, is formed by removal of the thienylethyl side chain and has substantially lower opioid activity.[10]
Pharmacology[edit]
Mechanism of action
Sufentanil is a highly selective full agonist at the µ-opioid receptor (μ-opioid), binding with sub-nanomolar affinity — the highest measured among approved opioid drugs in uniform assay conditions.[11] This affinity substantially exceeds that of fentanyl.[11]
Activation of the MOR triggers inhibitory signaling that reduces neuronal excitability: intracellular signaling molecules suppress excitatory activity, potassium channels open to quiet the neuron, and calcium channels close to block neurotransmitter release.[2] These combined actions suppress pain transmission, produce sedation, and depress respiratory drive.
A distinguishing feature is sufentanil's high endocytotic efficacy — it efficiently drives receptor internalization and recycling after activation. This may slow the development of analgesic tolerance compared to morphine, which is a poor inducer of receptor internalization. However, the same property facilitates compensatory upregulation of excitatory signaling pathways, a cellular hallmark of physical dependence.[12]
Unlike meperidine, remifentanil, and tramadol, sufentanil does not interact with α₂-adrenoceptors at any tested concentration.[13] This exceptional selectivity means it lacks the anti-shivering and sympatholytic effects seen with those other opioids.
Pharmacokinetics
After intravenous administration, sufentanil follows a three-compartment distribution model.[14] It leaves the bloodstream rapidly — approximately 98% of an IV dose redistributes into tissues within 30 minutes. This rapid tissue uptake, rather than metabolic elimination, governs the short clinical duration of action at standard analgesic doses.[14]
The terminal half-life is approximately 2.7 hours in adults. Protein binding is approximately 93% in healthy adults and 79% in neonates, with alpha-1-acid glycoprotein as the primary carrier.[1]
Sufentanil is metabolized in the liver primarily by the CYP3A4 enzyme, producing norsufentanil as the major metabolite.[15] Norsufentanil has substantially lower opioid activity.[10] Approximately 80% of a dose is excreted within 24 hours, with only ~2% eliminated as unchanged drug.[1]
Age-dependent variation
Elimination half-life varies dramatically with age: approximately 1.6 hours in children, 2.7 hours in adults, and approximately 7.2 hours in neonates — a nearly threefold increase reflecting immature liver metabolism that necessitates careful dose adjustment in newborns.[16]
Route-specific behavior
After epidural administration, sufentanil is absorbed more slowly from the injection site, producing a "flip-flop" pattern in which absorption — not elimination — becomes the rate-limiting step, extending the duration of effect.[17]
During cardiopulmonary bypass, sufentanil levels drop approximately 25% at initiation due to dilution, then rebound effect approximately 50% after bypass ends.[18][19]
Neuroscience[edit]
Where it acts
Sufentanil's analgesic effects engage two interconnected systems. In the brainstem, µ-opioid receptor activation in the periaqueductal gray triggers descending inhibition of pain signals at the spinal cord.[2] At the spinal level, sufentanil directly suppresses pain transmission in the dorsal horn — a mechanism exploited in epidural and spinal anesthesia.
The reinforcing and euphorigenic properties arise from µ-opioid receptor activation in the ventral tegmental area and nucleus accumbens — the brain's core reward circuit.[2] Receptor activation disinhibits dopamine neurons, flooding reward regions with dopamine. The most dangerous effect — respiratory depression — results from µ-receptor activation in brainstem breathing centers, particularly the pre-Bötzinger complex, where it slows respiratory rhythm and reduces the drive to breathe.[1]
Tolerance and neuroadaptation
Chronic exposure rewires signaling at the molecular level. In the spinal cord, µ-opioid receptors uncouple from their normal inhibitory signaling partners.[20] In higher brain regions, the receptor's signaling actually reverses — switching from inhibitory to excitatory through reorganization within specialized membrane compartments.[21] This signaling reversal is a molecular marker of opioid dependence.
Sufentanil can also paradoxically increase pain sensitivity. In animal models, this pain enhancement was mediated by kinin B2 receptors — a pathway distinct from the mechanisms implicated in morphine-induced hyperalgesia.[22] This difference may explain why switching from morphine to sufentanil has resolved hyperalgesia in clinical settings.[23]
Several fundamental questions remain unanswered. Whether sufentanil's high receptor internalization efficiency translates to measurably slower tolerance development in humans has never been tested in controlled comparison with morphine at equivalent doses. No data exist on sufentanil's functional selectivity — the balance between different signaling pathways that determines the ratio of analgesia to respiratory depression — despite intense current interest in this property for opioid drug design.
Subjective Effects[edit]
Sufentanil produces the characteristic experience of a pure, high-potency µ-opioid agonist. Physical pain is extinguished rapidly and completely, accompanied by deep sedation, anxiolysis, and a warm euphoria that narrows consciousness to a quiet, undifferentiated stillness. At analgesic doses, the experience is dominated by relief and calm; at higher doses, awareness compresses toward loss of consciousness with little perceptual transition. Intravenous administration produces near-instantaneous onset with a razor-thin margin between analgesia and loss of consciousness, while sublingual and intranasal routes allow a slightly more gradual trajectory.
Relative to fentanyl, sufentanil produces comparable qualitative effects at 5–10× lower doses, with clinical literature noting superior hemodynamic stability. Compared to morphine, the experience is compressed into minutes rather than hours when given intravenously, with less nausea and histamine release. The pharmacological profile is "cleaner" than agents like tramadol or meperidine — lacking α2-adrenergic or serotonergic contributions, the experience is purely opioid in character, without the additional dimensions those mechanisms introduce.
Effect Grid
Common intravenous doses (5–10 µg absolute) produce clear pain suppression, moderate sedation, and noticeable euphoria — a warm, enveloping sense of wellbeing characteristic of mu-opioid activation. Pupil constriction is pronounced. Thought deceleration and mild cognitive impairment are present; focus suppression and motivation decline.
Respiratory depression is measurable — breathing slows and becomes shallower. Nausea affects a minority of users. Bodily heaviness and muscle relaxation are moderate. Constipation onset begins with gastrointestinal slowing. Motor control impairment is mild. Anxiety suppression becomes significant.
The peak experience lasts 5–10 minutes, with residual effects persisting 30–60 minutes as redistribution occurs. Emotional suppression may flatten affect beyond simple anxiolysis.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Visual haze / noise · Visual processing suppression
Breathing alteration · Constipation · Physical fatigue · Body high · Bodily heaviness · Muscle relaxation · Tactile euphoria · Nausea · Dizziness · Abnormal heartbeat · Spontaneous body sensations · Muscle tension · Dry mouth · Temperature dysregulation · Sexual arousal suppression · Appetite suppression · Heart rate perception changes · Vomiting · Excessive sweating · Tingling / electric sensations · Body schema distortion · Involuntary body movements · Nasal congestion · Restlessness · Pain enhancement · Bodily dissociation
Body high · Bodily heaviness · Muscle relaxation · Tactile euphoria · Nausea · Dizziness · Spontaneous body sensations · Muscle tension · Dry mouth · Temperature dysregulation · Sexual arousal suppression · Appetite suppression · Heart rate perception changes · Vomiting · Excessive sweating · Tingling / electric sensations · Body schema distortion · Involuntary body movements · Nasal congestion · Restlessness · Pain enhancement · Bodily dissociation
Information processing suppression · Thought deceleration · Analysis suppression · Cognitive euphoria · Memory suppression · Motivation suppression · Creativity suppression · Language suppression · Memory fragmentation · Suggestibility enhancement · Confusion · Thought disorganization · Cognitive dysphoria · Delusions of sobriety · Amnesia · Delirium · Delusions
Cognitive euphoria · Memory suppression · Motivation suppression · Creativity suppression · Language suppression · Memory fragmentation · Confusion · Thought disorganization · Cognitive dysphoria · Delusions of sobriety · Amnesia · Delirium · Delusions
Anhedonia · Anxiety · Dysphoria · Irritability
Social disconnection · Sociability enhancement · Depersonalization · Derealization · Cognitive disconnection
Cognitive disconnection
Timeline
Rapid warmth spreading from the injection site, initial analgesia, and the first wave of sedation. Effects are perceptible almost immediately due to sufentanil's 1. 4-minute rapid distribution half-life.
Maximum analgesia, euphoria, and sedation. Respiratory depression reaches its greatest intensity. Pupil constriction is maximal.
Gradual return of awareness as sufentanil redistributes to peripheral tissues — 98% leaves plasma within 30 minutes. Analgesia and sedation fade progressively. Residual drowsiness and mild cognitive dulling may persist.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- morphine · fentanyl · DADLE
Toxicity
Acute toxicity
The primary danger of sufentanil is dose-dependent respiratory depression — breathing slows progressively and can stop entirely. In preclinical studies, sufentanil showed the highest safety margin of any major opioid tested, and all effects were reversed by opioid antagonists.[4]
Respiratory depression is the primary cause of death in sufentanil overdose. Sufentanil suppresses the drive to breathe via µ-opioid receptor activation in brainstem respiratory centers, leading to progressive oxygen deprivation and respiratory arrest if untreated.[2] Despite the wide preclinical safety margin, the distance between analgesic and life-threatening respiratory depression in humans is narrow enough that all clinical use requires continuous respiratory monitoring and immediate access to airway management.
Chest wall rigidity
Rapid intravenous injection can cause severe chest wall rigidity — involuntary muscle contraction that physically prevents adequate breathing even when the drive to breathe is intact.[2] This effect is managed in clinical settings with muscle-relaxing agents.
Overdose reversal
Sufentanil overdose is reversible with naloxone. Sufentanil's exceptionally high receptor affinity means higher or repeated doses of naloxone may be needed compared to morphine or fentanyl overdose.[19]
Respiratory depression from sufentanil may outlast the duration of naloxone, necessitating repeated dosing or continuous infusion with ongoing respiratory monitoring.
Fatal cases
Published fatality data specific to sufentanil are sparse. A review of self-administered anesthetics among healthcare professionals in Berlin (1998–2011) attributed one death to sufentanil, though the compound was undetectable at autopsy due to decomposition.[6] Benzodiazepines contributed to fatal respiratory depression in four of nine cases in that series.[6]
Chronic toxicity
No sufentanil-specific long-term toxicity studies in humans exist. Chronic risks are inferred from the opioid class: prolonged use produces hormonal disruption, immune suppression, and psychological dependence.[11] inferred
Psychological risks
Sufentanil's psychological risks mirror those of all potent opioids: euphoria-driven compulsive use, psychological dependence, and the cognitive and motivational consequences of chronic exposure. No controlled studies exist characterizing its specific psychological risk profile outside clinical settings. Documented misuse predominantly involves healthcare professionals with anesthesia access.[6]
Tolerance and dependence
Tolerance
Sufentanil's high receptor recycling efficiency may slow analgesic tolerance development compared to morphine.[20] But the same process drives compensatory upregulation of excitatory signaling — the cellular basis of physical dependence and withdrawal.[20] At the molecular level, spinal opioid receptors uncouple from inhibitory pathways,[15] and supraspinal receptor signaling switches from inhibitory to excitatory.[16]
Cross-tolerance
In animal studies, sufentanil-tolerant subjects showed cross-tolerance to morphine given directly into the brain but not to intravenous morphine[21] — demonstrating that route of administration shapes how cross-tolerance is expressed.
Physical dependence
Physical dependence develops with sustained use. In pediatric intensive care data, treatment duration exceeding 177 hours predicts withdrawal syndrome with 81% sensitivity and 94% specificity.[22]
Drug Interactions
CNS depressant combinations
The most dangerous interaction class is additive-to-synergistic respiratory depression with other sedatives. Benzodiazepines synergistically amplify sufentanil's respiratory depression — documented in forensic death reports[6] and clinical anesthesia literature.[23]
Alcohol, GHB, and GBL add to sufentanil's depression of breathing and consciousness. These combinations carry lethal risk; no sufentanil-specific controlled data exist for these pairings. inferred
Combining sufentanil with tramadol carries dual risk: additive respiratory depression, plus a theoretical risk of dangerous serotonin overload from tramadol's serotonergic activity. Sufentanil itself does not appear to inhibit serotonin reuptake.[24] safety citation needed
Ketamine and sufentanil are co-administered routinely in clinical anesthesia; at high combined doses, significant respiratory depression can occur. safety citation needed
- CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, ritonavir, grapefruit juice) raise sufentanil levels, intensifying all effects including respiratory depression
- CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St. John's wort) lower sufentanil levels, risking inadequate pain suppression or precipitating withdrawal in dependent individuals
MAOIs
No sufentanil-specific MAOI interaction data exist. The fentanyl class carries lower serotonin syndrome risk than meperidine or tramadol because it does not significantly inhibit serotonin reuptake, but combined use with MAOIs remains a general opioid class contraindication. safety citation needed
Contraindications
10 knownAbsolute contraindications
- Known allergy to sufentanil or other opioid agonists[2]
- Absence of resuscitation equipment and trained personnel — sufentanil requires medically supervised settings with immediate airway management access[2]
Relative contraindications
- Impaired breathing or airway disease — baseline respiratory compromise narrows the margin between therapeutic and lethal doses
- Newborns — elimination is prolonged to approximately 7.2 hours due to immature liver metabolism[13]
- Liver impairment — reduced liver function prolongs drug exposure
- Concurrent CYP3A4 inhibitors — raise sufentanil levels and intensify all effects including respiratory depression[14]
- Head injury or raised brain pressure — respiratory depression raises carbon dioxide, which increases blood flow and pressure in the brain[2]
Harm Reduction[edit]
Forms & Identification
Sufentanil in medical settings is a clear aqueous solution (50 µg/mL injection) or a small sublingual tablet (Dsuvia, 30 µg). Outside hospitals, identification is functionally impossible — active doses are measured in micrograms, far below the threshold of any visual, taste, or smell assessment.
The extreme potency makes measuring errors lethal. A dose calculated for fentanyl applied to sufentanil delivers 5–10× the intended opioid effect. Fentanyl test strips can confirm an anilidopiperidine is present but cannot identify the specific structural analog or its concentration.
Guidelines
- Never use alone. Respiratory depression can render a person unconscious and unable to self-rescue. A trained observer with naloxone is the minimum safety requirement.
- Never estimate doses. Sufentanil is active in single-digit micrograms. Standard scales cannot measure these quantities. Only pharmaceutical-grade preparations with verified concentrations approach safe dosing.
- Never combine with other depressants. Benzodiazepines, alcohol, GHB, and other sedatives synergistically increase the risk of fatal respiratory depression.
- Assume any unverified substance is dangerous. Sufentanil cannot be reliably identified outside a laboratory. Treat any claimed sufentanil as potentially misdosed.
- Keep naloxone accessible. Multiple doses may be needed — sufentanil's high receptor affinity can require higher or repeated naloxone administration compared to other opioids.
Set & Setting
Sufentanil is not a substance with a recreational set-and-setting framework. Safe administration requires continuous respiratory monitoring, airway management equipment, and trained personnel — conditions present only in operating rooms, intensive care units, and supervised acute pain settings.
The critical "setting" requirement is the physical presence of someone trained in airway management with naloxone immediately accessible. The physiological context matters far more than the psychological set: sufentanil's primary danger is respiratory, not psychological.
Aftercare & integration. Following sufentanil exposure in a medical context, residual sedation and cognitive impairment may persist for hours after apparent recovery. Do not drive, operate machinery, or make important decisions for at least 24 hours after the last dose.
The psychological aftermath of opioid-related respiratory depression or overdose can include anxiety, hypervigilance around breathing, and intrusive memories. Professional support — counseling or trauma-informed care — may help process these experiences. Monitor for delayed respiratory depression, particularly after epidural administration.
Recovery & Support
Physical dependence develops rapidly with sustained use — in pediatric ICU data, withdrawal becomes likely after approximately one week of continuous infusion.[22] Withdrawal should be managed under medical supervision with gradual dose tapering, not abrupt discontinuation.
For individuals with opioid use disorder involving sufentanil or related compounds, evidence-based treatments include medication-assisted therapy (methadone, buprenorphine), behavioral counseling, and peer support. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. The occupational context of most documented misuse — healthcare professionals with anesthesia access — may require specialized programs addressing both substance use and workplace dimensions.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing is slow (fewer than 8 breaths per minute), shallow, or has stopped
- Lips, fingertips, or face appear blue or gray
- Person is unresponsive to voice or firm stimulation
- Gurgling, choking, or snoring sounds during unconsciousness
- Chest wall rigidity — the chest feels stiff and does not move with breathing attempts
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available — intranasal (4 mg) or intramuscular. Higher or repeated doses may be needed due to sufentanil's high receptor affinity[19]
- 3. If breathing has stopped and no naloxone is available, begin rescue breathing
- 4. Place the person in the recovery position if breathing but unconscious
- 5. Do not leave the person alone — respiratory depression from sufentanil may outlast naloxone's duration, requiring repeated doses
- 6. Do not induce vomiting
What to tell the dispatcher: State that the person is not breathing or breathing very slowly, that an opioid is suspected, whether naloxone has been given, and the approximate time symptoms began. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Legal Status[edit]
Sufentanil is a controlled substance in all major jurisdictions, listed under the 1961 United Nations Single Convention on Narcotic Drugs and subject to national scheduling in signatory countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | FDA-approved as injection (1984, NDA 019050) and sublingual tablet (Dsuvia, 2018, NDA 209128). Prescription required; no OTC availability. DEA Schedule II since initial approval.[2] |
| United Kingdom | Class A (Misuse of Drugs Act 1971); Schedule 2 (Misuse of Drugs Regulations 2001) | Added via Modification Order 1983. Available for medical use under strict controls; maximum penalties for unauthorized possession and supply as for Class A substances.[25] |
| European Union | National narcotic schedules (member state level) | Approved for medical use in multiple EU member states. Dzuveo (sufentanil sublingual tablet) marketed in Europe. Controlled under national laws consistent with the 1961 UN Single Convention. |
| Australia | Controlled substance (Poisons Standard) | Listed by the Office of Drug Control (ODC).[26] |
| Canada | Controlled substancecitation needed | Scheduling confirmation not retrieved. Expected to be controlled under the Controlled Drugs and Substances Act consistent with UN treaty obligations. |
The class-wide scheduling of fentanyl-related substances in the United States, implemented in February 2018, provided additional control mechanisms for novel fentanyl analogs. Sufentanil itself was already individually scheduled and was not affected by this class action.[27]
Legal status varies by jurisdiction and changes over time. The information above reflects available data as of this article's publication and is not legal advice. Verify current local status with the relevant authorities before acting on it.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- morphine · fentanyl · DADLE
Toxicity
Acute toxicity
Sufentanil's acute danger is the same as all potent µ-opioid agonists: dose-dependent respiratory depression that can progress to respiratory arrest and death. In preclinical studies, sufentanil demonstrated the highest therapeutic index (safety margin between effective and lethal dose) of any major opioid tested — vastly exceeding morphine and fentanyl under the same conditions.[5] All effects were reversed by opioid antagonists in these studies.[5]
Respiratory depression is the primary cause of death in sufentanil overdose. Sufentanil suppresses the drive to breathe via µ-opioid receptor activation in brainstem respiratory centers, leading to progressive oxygen deprivation and respiratory arrest if untreated.[1] Despite the wide preclinical safety margin, the distance between analgesic and life-threatening respiratory depression in humans is narrow enough that all clinical use requires continuous respiratory monitoring and immediate access to airway management.
Chest wall rigidity
Rapid intravenous injection can produce severe chest wall rigidity — involuntary skeletal muscle contraction that physically prevents adequate breathing even when the brain's respiratory drive is intact. This effect is managed in clinical settings with muscle-relaxing agents.[1]
Overdose reversal
Sufentanil overdose is reversible with naloxone. Due to sufentanil's exceptionally high receptor affinity, higher or repeated doses of naloxone may be required compared to morphine or fentanyl overdose. A 2026 study specifically evaluated intranasal naloxone (4 mg) for reversing sufentanil-induced respiratory depression, selecting sufentanil because of its higher receptor affinity than fentanyl.[24]
Respiratory depression from sufentanil may outlast the duration of naloxone, necessitating repeated dosing or continuous infusion with ongoing respiratory monitoring.
Fatal cases
Published fatality data specific to sufentanil are sparse. A review of deaths from self-administered IV anesthetics among healthcare professionals in Berlin (1998–2011) attributed one death to sufentanil, though the compound was undetectable at autopsy due to decomposition.[7] Benzodiazepines contributed to fatal respiratory depression through combined sedation in four of nine cases across the series.[7]
Chronic toxicity
No sufentanil-specific long-term toxicity studies in humans have been published. Chronic risks are inferred from the opioid class: prolonged use produces hormonal disruption, immune suppression, and psychological dependence.[2] inferred
Psychological risks
Sufentanil's psychological risks mirror those of all potent µ-opioid agonists: euphoria-driven compulsive use, psychological dependence, and the cognitive and motivational consequences of chronic opioid exposure. No controlled studies have characterized sufentanil's specific psychological risk profile outside clinical settings.
At analgesic doses below the anesthetic threshold, cognitive impairment, sedation, and decision impairment are expected. inferred Documented misuse predominantly involves healthcare professionals with access to anesthesia supplies rather than recreational users.[7]
Tolerance and dependence
Tolerance
Sufentanil's high receptor internalization efficiency promotes receptor recycling and resensitization, which may slow analgesic tolerance compared to morphine.[12] However, this same property drives compensatory upregulation of excitatory signaling pathways — the cellular basis of physical dependence and withdrawal.[12]
At the molecular level, chronic exposure uncouples spinal µ-opioid receptors from their inhibitory signaling partners[20] and switches supraspinal receptor signaling from inhibitory to excitatory.[21]
Cross-tolerance
In animal studies, sufentanil-tolerant subjects showed cross-tolerance to morphine administered directly into the brain but not to intravenous morphine — demonstrating that the route of administration modulates how cross-tolerance is expressed.[25]
Physical dependence
Physical dependence develops with sustained use. In pediatric intensive care settings, treatment duration exceeding 177 hours predicts withdrawal syndrome with 81% sensitivity and 94% specificity.[26] Genetic variations in drug-metabolizing enzymes influenced dosing requirements but were not independently associated with withdrawal risk.[26]
Drug Interactions
CNS depressant combinations
The most dangerous interaction class is additive-to-synergistic respiratory depression with other depressants. Benzodiazepines synergistically increase sufentanil's respiratory depressant effects — this interaction is directly documented in both forensic death reports[7] and clinical anesthesia literature.[27]
Alcohol, GHB, and GBL combine with sufentanil to produce additive depression of breathing and consciousness. These combinations carry lethal risk based on pharmacological class reasoning — no sufentanil-specific controlled interaction data exist for these pairings. inferred
Tramadol combined with sufentanil carries dual risk: additive respiratory depression from opioid effects, and theoretical serotonin syndrome risk from tramadol's serotonergic activity. Sufentanil itself does not appear to inhibit serotonin reuptake.[13] safety citation needed
Ketamine and sufentanil are routinely co-administered in clinical anesthesia; at high combined doses, significant respiratory depression can occur. safety citation needed
- CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, ritonavir, grapefruit juice) may increase sufentanil levels, intensifying all effects including respiratory depression
- CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St. John's wort) may reduce sufentanil levels, risking inadequate pain suppression or precipitating withdrawal in dependent individuals
MAOIs
No sufentanil-specific MAOI interaction data exist. The fentanyl class is considered lower-risk for serotonin syndrome than meperidine or tramadol due to the absence of significant serotonin reuptake inhibitor, but combined use with MAOIs remains a general opioid class contraindication. safety citation needed
Contraindications
10 knownAbsolute contraindications
- Known allergy to sufentanil or other opioid agonists[1]
- Absence of resuscitation equipment and trained personnel — sufentanil is indicated only for medically supervised settings with immediate access to airway management[1]
Relative contraindications
- Impaired breathing or airway disease — baseline respiratory compromise narrows the margin between therapeutic and lethal respiratory depression
- Newborns — half-life is prolonged to approximately 7.2 hours (versus 2.7 hours in adults) due to immature liver metabolism[16]
- Liver impairment — sufentanil clearance depends on liver blood flow; reduced liver function prolongs exposure
- Concurrent CYP3A4 inhibitors — co-administration with strong CYP3A4 inhibitors increases sufentanil levels and intensifies all effects including respiratory depression[15]
- Head injury or raised pressure inside the skull — opioid-induced respiratory depression increases carbon dioxide levels, which can increase blood flow and pressure in the brain[1]
Harm Reduction[edit]
Forms & Identification
Sufentanil in legitimate medical settings is a clear aqueous solution (50 µg/mL injection) or a small sublingual tablet (30 µg Dsuvia). Outside hospitals, identification is functionally impossible — the active doses are measured in micrograms, far below the threshold of any visual or physical assessment. Any powder or liquid claimed to be sufentanil cannot be verified by appearance, taste, or smell.
The extreme potency means volumetric errors are lethal. A dose measured for fentanyl applied to sufentanil would deliver 5–10× the intended opioid effect. Fentanyl test strips confirm an anilidopiperidine is present but cannot distinguish which structural analog or its concentration.
Guidelines
- Never use alone. Respiratory depression can render a person unconscious and unable to self-rescue. A trained observer with naloxone is the minimum safety requirement.
- Never estimate doses. Sufentanil is active in single-digit micrograms. Standard scales cannot measure these quantities. Only pharmaceutical-grade preparations with verified concentrations approach safe dosing.
- Never combine with other depressants. Benzodiazepines, alcohol, GHB, and other sedatives synergistically increase the risk of fatal respiratory depression.
- Assume any unverified substance is dangerous. Sufentanil cannot be reliably identified outside a laboratory. Treat any claimed sufentanil as potentially misdosed.
- Keep naloxone accessible. Multiple doses may be needed — sufentanil's high receptor affinity can require higher or repeated naloxone administration compared to other opioids.
Set & Setting
Sufentanil is not a substance with a recreational set-and-setting framework. It exists almost exclusively in monitored medical environments — operating rooms, intensive care units, and supervised acute pain management. Any use outside these settings lacks the continuous respiratory monitoring, airway management equipment, and trained personnel that define safe administration.
The critical "setting" requirement is the physical presence of someone trained in airway management with naloxone immediately accessible. The psychological set is less relevant than the physiological context: sufentanil's danger is respiratory, not psychological.
Aftercare & integration. Following sufentanil exposure in a medical context, residual sedation and cognitive impairment may persist for hours after apparent recovery. Do not drive, operate machinery, or make important decisions for at least 24 hours after the last dose.
For individuals who have experienced opioid-related respiratory depression or overdose, the psychological aftermath can include anxiety, hypervigilance around breathing, and intrusive memories. Professional support — counseling or trauma-informed care — may be beneficial for processing these experiences. Monitor for delayed respiratory depression, particularly after epidural administration where absorption-limited kinetics can extend the period of risk.
Recovery & Support
Physical dependence on sufentanil develops rapidly with sustained use — in pediatric ICU data, withdrawal becomes likely after approximately one week of continuous infusion.[26] Withdrawal should be managed under medical supervision with gradual dose tapering rather than abrupt discontinuation.
For individuals with opioid use disorder involving sufentanil or related compounds, evidence-based treatments include medication-assisted therapy (methadone, buprenorphine), behavioral counseling, and peer support programs. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. The occupational context of most documented sufentanil misuse — healthcare professionals with anesthesia access — may require specialized professional assistance programs that address both the substance use and workplace dimensions of recovery.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing is slow (fewer than 8 breaths per minute), shallow, or has stopped
- Lips, fingertips, or face appear blue or gray
- Person is unresponsive to voice or firm stimulation
- Gurgling, choking, or snoring sounds during unconsciousness
- Chest wall rigidity — the chest feels stiff and does not move with breathing attempts
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available — intranasal (4 mg) or intramuscular. Higher or repeated doses may be needed due to sufentanil's high receptor affinity[24]
- 3. If breathing has stopped and no naloxone is available, begin rescue breathing
- 4. Place the person in the recovery position if breathing but unconscious
- 5. Do not leave the person alone — respiratory depression from sufentanil may outlast naloxone's duration, requiring repeated doses
- 6. Do not induce vomiting
What to tell the dispatcher: State that the person is not breathing or breathing very slowly, that an opioid is suspected, whether naloxone has been given, and the approximate time symptoms began. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Legal Status[edit]
Sufentanil is a controlled substance in all major jurisdictions, reflecting its classification as a potent synthetic opioid with high abuse potential and accepted medical use. It is listed under the 1961 United Nations Single Convention on Narcotic Drugs and is subject to national scheduling in countries party to that convention.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | FDA-approved as injection (1984, NDA 019050) and sublingual tablet (Dsuvia, 2018, NDA 209128). Prescription required; no OTC availability. DEA Schedule II since initial approval.[1] |
| United Kingdom | Class A (Misuse of Drugs Act 1971); Schedule 2 (Misuse of Drugs Regulations 2001) | Added via Modification Order 1983. Available for medical use under strict controls; maximum penalties for unauthorized possession and supply as for Class A substances.[28] |
| European Union | National narcotic schedules (member state level) | Approved for medical use in multiple EU member states. Dzuveo (sufentanil sublingual tablet) marketed in Europe. Controlled under national laws consistent with the 1961 UN Single Convention. |
| Australia | Controlled substance (Poisons Standard) | Listed by the Office of Drug Control (ODC).[29] |
| Canada | Controlled substancecitation needed | Scheduling confirmation not retrieved. Expected to be controlled under the Controlled Drugs and Substances Act consistent with UN treaty obligations. |
The class-wide scheduling of fentanyl-related substances in the United States, implemented in February 2018, provided additional control mechanisms for novel fentanyl analogs. Sufentanil itself was already individually scheduled and was not affected by this class action.[30]
Frequently asked questions
What is Sufentanil?
Sufentanil is a synthetic opioid of the anilidopiperidine class, approximately 500–1,000× more potent than morphine at the mu-opioid receptor. First synthesized at Janssen Pharmaceutica in 1974, it is used clinically in anesthesia and approved sublingually as Dsuvia (2018).
How long does Sufentanil last?
Total duration by route of administration — Intravenous: Unknown. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Sufentanil?
Psychedex publishes a dosage table for Sufentanil on this page covering these routes of administration: intravenous, sublingual. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Sufentanil?
The highest-severity documented interactions for Sufentanil: Benzodiazepines, Barbiturates (Lethal), GHB, Baclofen (Lethal), GHB, GBL (Lethal), Local anesthetics (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Sufentanil addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Sufentanil: tolerance builds moderate; cross-tolerance develops with morphine, fentanyl, DADLE, other mu-opioid receptor agonists. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4] ^abcdNiemegeers CJ, Schellekens KH, Van Bever WF, Janssen PA (1976) Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs — Arzneimittel-Forschung PMID:12772
- [5]
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]